ATE340562T1 - Cgmp pde-5 inhibitor enthaltende pharmazeutische formulierungen mit verzögerter freisetzung - Google Patents

Cgmp pde-5 inhibitor enthaltende pharmazeutische formulierungen mit verzögerter freisetzung

Info

Publication number: ATE340562T1
Authority: AT; Austria
Prior art keywords: inhibitor; pharmaceutical formulations; formulations containing; delayed release; release pharmaceutical
Prior art date: 1998-10-23

Application number

AT99946377T

Other languages

English (en)

Inventor

Elizabeth King

Ross James Macrae

Original Assignee

Pfizer Ireland Pharmaceuticals

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-23

Filing date

1999-10-04

Publication date

2006-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE340562(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-10-23 Priority claimed from GBGB9823192.1A external-priority patent/GB9823192D0/en

1998-11-16 Priority claimed from GBGB9825117.6A external-priority patent/GB9825117D0/en

1998-11-27 Priority claimed from GBGB9826392.4A external-priority patent/GB9826392D0/en

1999-10-04 Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals

2006-10-15 Application granted granted Critical

2006-10-15 Publication of ATE340562T1 publication Critical patent/ATE340562T1/de

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Gynecology & Obstetrics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT99946377T 1998-10-23 1999-10-04 Cgmp pde-5 inhibitor enthaltende pharmazeutische formulierungen mit verzögerter freisetzung ATE340562T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9823192.1A GB9823192D0 (en)	1998-10-23	1998-10-23	Pharmaceutical formulations
GBGB9825117.6A GB9825117D0 (en)	1998-11-16	1998-11-16	Pharmaceutical formulations
GBGB9826392.4A GB9826392D0 (en)	1998-11-27	1998-11-27	Pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
ATE340562T1 true ATE340562T1 (de)	2006-10-15

Family

ID=27269526

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99946377T ATE340562T1 (de)	1998-10-23	1999-10-04	Cgmp pde-5 inhibitor enthaltende pharmazeutische formulierungen mit verzögerter freisetzung

Country Status (44)

Country	Link
US (1)	US6964780B1 (de)
EP (1)	EP1123088B1 (de)
JP (1)	JP2002528408A (de)
KR (1)	KR20010075659A (de)
CN (1)	CN1324233A (de)
AP (1)	AP2001002125A0 (de)
AT (1)	ATE340562T1 (de)
AU (1)	AU756509B2 (de)
BG (1)	BG65323B1 (de)
BR (1)	BR9914718A (de)
CA (1)	CA2348086C (de)
CO (1)	CO5160262A1 (de)
CR (1)	CR6326A (de)
CY (1)	CY1106239T1 (de)
CZ (1)	CZ20011427A3 (de)
DE (1)	DE69933383T2 (de)
DK (1)	DK1123088T3 (de)
DZ (1)	DZ2923A1 (de)
EA (1)	EA004068B1 (de)
EE (1)	EE200100235A (de)
ES (1)	ES2272082T3 (de)
GT (1)	GT199900184A (de)
HK (1)	HK1041818A1 (de)
HR (1)	HRP20010285A2 (de)
HU (1)	HUP0104318A3 (de)
ID (1)	ID28232A (de)
IL (1)	IL141764A (de)
IS (1)	IS5865A (de)
MA (1)	MA26700A1 (de)
MX (1)	MXPA01004011A (de)
MY (1)	MY130727A (de)
NO (1)	NO20011933L (de)
NZ (1)	NZ510275A (de)
OA (1)	OA11664A (de)
PA (1)	PA8484301A1 (de)
PE (1)	PE20001286A1 (de)
PL (1)	PL195789B1 (de)
PT (1)	PT1123088E (de)
SK (1)	SK286473B6 (de)
TR (1)	TR200101103T2 (de)
TW (1)	TW577756B (de)
UA (1)	UA67802C2 (de)
UY (1)	UY25765A1 (de)
WO (1)	WO2000024383A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL135462A0 (en) *	1997-11-12	2001-05-20	Bayer Ag	2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
EP2020229A1 (de)	1998-11-02	2009-02-04	Elan Pharma International Limited	Mehrpartikelmodifizierte Freisetzungszusammensetzung
CN102716101A (zh)	1999-10-29	2012-10-10	欧罗赛铁克股份有限公司	控释氢可酮制剂
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
JP4588973B2 (ja) *	2000-09-06	2010-12-01	田辺三菱製薬株式会社	経口投与用製剤
CN100518827C (zh)	2000-10-30	2009-07-29	欧罗赛铁克股份有限公司	控释氢可酮制剂
EP1366760B1 (de) *	2001-02-15	2010-06-30	Mitsubishi Tanabe Pharma Corporation	Tabletten, die in der mundhöhle schnell zerfallen
US10675280B2 (en)	2001-10-20	2020-06-09	Sprout Pharmaceuticals, Inc.	Treating sexual desire disorders with flibanserin
UA78974C2 (en)	2001-10-20	2007-05-10	Boehringer Ingelheim Pharma	Use of flibanserin for treating disorders of sexual desire
ITMI20020515A1 (it) *	2002-03-12	2003-09-12	Jagotec Ag	Sistema per il rilasco controllato di uno o piu' principi attivi
GB0318824D0 (en) *	2003-08-11	2003-09-10	Glaxo Group Ltd	Novel composition
DE102004023069A1 (de) *	2004-05-11	2005-12-08	Bayer Healthcare Ag	Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
KR101292492B1 (ko)	2004-05-11	2013-08-01	이모셔널 브레인 비.브이.	약제학적 제형물 및 여성 성기능 부전의 치료에서 그것의용도
GB0421121D0 (en) *	2004-09-22	2004-10-27	Natrocell Technologies Ltd	Composite rodenticide
DE102005001989A1 (de) *	2005-01-15	2006-07-20	Bayer Healthcare Ag	Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de)	2005-03-01	2006-09-07	Bayer Healthcare Ag	Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) *	2005-03-01	2006-09-07	Bayer Healthcare Ag	Arzneiformen mit kontrollierter Bioverfügbarkeit
US20090118211A1 (en) *	2005-06-27	2009-05-07	Daniel Drai	Compositions and Methods for Enhancement of Sexual Function
EP1912650B8 (de)	2005-08-03	2017-10-18	Sprout Pharmaceuticals, Inc.	Verwendung von flibanserin bei der behandlung von fettsucht
JP2009509984A (ja) *	2005-09-29	2009-03-12	バイエル・ヘルスケア・アクチェンゲゼルシャフト	泌尿器系障害の処置用のｐｄｅ阻害剤およびそれらの組合せ
EP1945214A1 (de)	2005-10-29	2008-07-23	Boehringer Ingelheim International GmbH	Benzimidazolon-derivate zur behandlung von prämenstruellen und anderen sexuellen störungen der frau
EP1790343A1 (de)	2005-11-11	2007-05-30	Emotional Brain B.V.	Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
DE602007004615D1 (de)	2006-06-30	2010-03-18	Boehringer Ingelheim Pharma	Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
BRPI0716439B8 (pt)	2006-08-14	2021-05-25	Boehringer Ingelheim Int	sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos
JP5220746B2 (ja)	2006-08-25	2013-06-26	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	制御放出システム及びその製造方法
EP1925307A1 (de) *	2006-11-03	2008-05-28	Emotional Brain B.V.	Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion
WO2008115797A1 (en) *	2007-03-16	2008-09-25	Pavo, Inc.	Therapeutic compositions and methods
CA2689638A1 (en) *	2007-06-13	2008-12-18	Bayer Schering Pharma Aktiengesellschaft	Pde inhibitors for the treatment of hearing impairment
UY31335A1 (es)	2007-09-12	2009-04-30		Tratamiento de sintomas vasomotores
WO2009098697A1 (en) *	2008-02-08	2009-08-13	Dexxon Ltd.	Modafinil and sildenafil dosage forms
BRPI0823356A2 (pt)	2008-12-12	2015-06-16	Rhein Siegfried Sa De Cv	Composição de liberação pulsátil de sildenafil e processo para prepará-la
KR101004205B1 (ko) *	2008-12-17	2010-12-24	동아제약주식회사	유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
EA015250B9 (ru) *	2010-11-19	2013-10-30	Тева Фармасьютикал Индастриз, Лтд.	Таблетка силденафила, обеспечивающая модифицированную фармакокинетику, и способ ее изготовления
PH12013502325A1 (en)	2011-05-13	2014-02-10	Eb Ip Hybritabs B V	Drug delivery system
US20140328911A1 (en) *	2011-07-22	2014-11-06	Pom Wonderful. Llc	Compositions comprising pomegranate polyphenols in combination with erectile dysfunction-treating compounds, and methods of treating erectile dysfunction therewith
WO2017168174A1 (en) *	2016-04-02	2017-10-05	N4 Pharma Uk Limited	New pharmaceutical forms of sildenafil
CN113995727B (zh) *	2021-11-08	2023-04-07	山东鲁抗医药股份有限公司	一种5型磷酸二酯酶抑制剂片剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3952741A (en)	1975-01-09	1976-04-27	Bend Research Inc.	Controlled release delivery system by an osmotic bursting mechanism
JPS54119021A (en) *	1978-03-06	1979-09-14	Nippon Kayaku Co Ltd	Carcinostatic agent
CH648754A5 (en) *	1979-08-16	1985-04-15	Ciba Geigy Ag	Pharmaceutical slow release tablet
JPS5748908A (en) *	1980-09-08	1982-03-20	Kyorin Pharmaceut Co Ltd	Prolonged release type nicomol pharmaceutical
FR2624732B1 (fr)	1987-12-21	1991-02-15	Synthelabo	Formulation pharmaceutique a liberation prolongee
MC2025A1 (fr) *	1988-04-20	1990-04-25	Asta Pharma Ag	Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IT1229856B (it) *	1989-04-20	1991-09-13	Recordati Chem Pharm	Compresse a rilascio controllato contenenti flavossato.
US5474784A (en)	1990-03-02	1995-12-12	British Technology Group Limited	Dispensing device
GB9013750D0 (en)	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
GB9114760D0 (en)	1991-07-09	1991-08-28	Pfizer Ltd	Therapeutic agents
ES2149250T3 (es) *	1993-04-23	2000-11-01	Novartis Ag	Dispositivo para la administracion de medicamentos con liberacion controlada.
GB9311920D0 (en) *	1993-06-09	1993-07-28	Pfizer Ltd	Therapeutic agents
US5464633A (en)	1994-05-24	1995-11-07	Jagotec Ag	Pharmaceutical tablets releasing the active substance after a definite period of time
US5656629A (en) *	1995-03-10	1997-08-12	Sanofi Winthrop, Inc.	6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US5888534A (en)	1995-06-13	1999-03-30	Pentech Pharmaceuticals, Inc.	Controlled release of drugs delivered by sublingual or buccal administration
GB9514464D0 (en) *	1995-07-14	1995-09-13	Glaxo Lab Sa	Medicaments
GB9523752D0 (en) *	1995-11-21	1996-01-24	Pfizer Ltd	Pharmaceutical formulations
WO1997048382A2 (en) *	1996-06-18	1997-12-24	Otsuka Pharmaceutical Co., Ltd.	Multiple-unit type prolonged action drug preparation
JPH1067657A (ja) *	1996-06-18	1998-03-10	Otsuka Pharmaceut Co Ltd	マルチプルユニット型持続性製剤
YU31599A (sh) *	1997-01-06	2000-03-21	Pfizer Inc.	Brzo oslobadjajući i za ukus maskirajući farmaceutski oblik doze
US5874418A (en) *	1997-05-05	1999-02-23	Cydex, Inc.	Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) *	1997-05-05	2000-04-04	Cydex, Inc.	Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6403597B1 (en) *	1997-10-28	2002-06-11	Vivus, Inc.	Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6277884B1 (en) *	1998-06-01	2001-08-21	Nitromed, Inc.	Treatment of sexual dysfunction with N-hydroxyguanidine compounds
DE69916627T2 (de) *	1998-09-04	2005-07-28	Ortho-Mcneil Pharmaceutical, Inc.	5-heterozyklyl-pyrazolo[4,3-d]pyrimidin-7-one für die behandlung von männlichen erectilen dysfunktionen

1999
- 1999-04-10 UA UA2001042718A patent/UA67802C2/uk unknown
- 1999-10-01 TW TW088116973A patent/TW577756B/zh not_active IP Right Cessation
- 1999-10-04 ES ES99946377T patent/ES2272082T3/es not_active Expired - Lifetime
- 1999-10-04 TR TR2001/01103T patent/TR200101103T2/xx unknown
- 1999-10-04 PL PL99347476A patent/PL195789B1/pl not_active IP Right Cessation
- 1999-10-04 IL IL141764A patent/IL141764A/en unknown
- 1999-10-04 AU AU58787/99A patent/AU756509B2/en not_active Ceased
- 1999-10-04 ID IDW20010891A patent/ID28232A/id unknown
- 1999-10-04 SK SK519-2001A patent/SK286473B6/sk unknown
- 1999-10-04 AT AT99946377T patent/ATE340562T1/de not_active IP Right Cessation
- 1999-10-04 CZ CZ20011427A patent/CZ20011427A3/cs unknown
- 1999-10-04 EA EA200100298A patent/EA004068B1/ru not_active IP Right Cessation
- 1999-10-04 AP APAP/P/2001/002125A patent/AP2001002125A0/en unknown
- 1999-10-04 PT PT99946377T patent/PT1123088E/pt unknown
- 1999-10-04 BR BR9914718-1A patent/BR9914718A/pt not_active Application Discontinuation
- 1999-10-04 OA OA1200100093A patent/OA11664A/en unknown
- 1999-10-04 HK HK02103588.0A patent/HK1041818A1/zh unknown
- 1999-10-04 MX MXPA01004011A patent/MXPA01004011A/es active IP Right Grant
- 1999-10-04 KR KR1020017005042A patent/KR20010075659A/ko not_active Ceased
- 1999-10-04 CA CA002348086A patent/CA2348086C/en not_active Expired - Fee Related
- 1999-10-04 WO PCT/IB1999/001619 patent/WO2000024383A1/en not_active Ceased
- 1999-10-04 CN CN99812510A patent/CN1324233A/zh active Pending
- 1999-10-04 EE EEP200100235A patent/EE200100235A/xx unknown
- 1999-10-04 HR HR20010285A patent/HRP20010285A2/xx not_active Application Discontinuation
- 1999-10-04 DK DK99946377T patent/DK1123088T3/da active
- 1999-10-04 NZ NZ510275A patent/NZ510275A/en unknown
- 1999-10-04 HU HU0104318A patent/HUP0104318A3/hu unknown
- 1999-10-04 EP EP99946377A patent/EP1123088B1/de not_active Expired - Lifetime
- 1999-10-04 JP JP2000577993A patent/JP2002528408A/ja active Pending
- 1999-10-04 DE DE69933383T patent/DE69933383T2/de not_active Expired - Fee Related
- 1999-10-18 PA PA19998484301A patent/PA8484301A1/es unknown
- 1999-10-20 MY MYPI99004535A patent/MY130727A/en unknown
- 1999-10-20 MA MA25820A patent/MA26700A1/fr unknown
- 1999-10-20 DZ DZ990223A patent/DZ2923A1/xx active
- 1999-10-21 PE PE1999001062A patent/PE20001286A1/es not_active Application Discontinuation
- 1999-10-22 US US09/425,622 patent/US6964780B1/en not_active Expired - Fee Related
- 1999-10-22 GT GT199900184A patent/GT199900184A/es unknown
- 1999-10-22 UY UY25765A patent/UY25765A1/es not_active Application Discontinuation
- 1999-10-22 CO CO99066970A patent/CO5160262A1/es unknown
2001
- 2001-02-27 IS IS5865A patent/IS5865A/is unknown
- 2001-03-14 CR CR6326A patent/CR6326A/es not_active Application Discontinuation
- 2001-04-19 NO NO20011933A patent/NO20011933L/no not_active Application Discontinuation
- 2001-04-24 BG BG105465A patent/BG65323B1/bg unknown
2006
- 2006-11-13 CY CY20061101644T patent/CY1106239T1/el unknown

Also Published As

Publication number	Publication date
UA67802C2 (uk)	2004-07-15
HUP0104318A3 (en)	2003-12-29
DK1123088T3 (da)	2007-01-02
CO5160262A1 (es)	2002-05-30
EP1123088A1 (de)	2001-08-16
SK286473B6 (sk)	2008-11-06
AU756509B2 (en)	2003-01-16
US6964780B1 (en)	2005-11-15
DZ2923A1 (fr)	2004-03-01
WO2000024383A1 (en)	2000-05-04
TW577756B (en)	2004-03-01
DE69933383T2 (de)	2007-02-01
UY25765A1 (es)	2001-08-27
MY130727A (en)	2007-07-31
MXPA01004011A (es)	2003-03-10
EE200100235A (et)	2002-08-15
EP1123088B1 (de)	2006-09-27
DE69933383D1 (de)	2006-11-09
EA200100298A1 (ru)	2001-08-27
TR200101103T2 (tr)	2001-09-21
CY1106239T1 (el)	2011-06-08
NO20011933L (no)	2001-06-25
CN1324233A (zh)	2001-11-28
GT199900184A (es)	2001-04-14
IL141764A (en)	2008-06-05
NO20011933D0 (no)	2001-04-19
PL347476A1 (en)	2002-04-08
BG105465A (bg)	2001-12-29
IS5865A (is)	2001-02-27
PA8484301A1 (es)	2000-09-29
CA2348086C (en)	2007-01-23
CR6326A (es)	2004-02-23
IL141764A0 (en)	2002-03-10
SK5192001A3 (en)	2002-09-10
CA2348086A1 (en)	2000-05-04
HUP0104318A2 (hu)	2002-03-28
HRP20010285A2 (en)	2002-06-30
HK1041818A1 (zh)	2002-07-26
PE20001286A1 (es)	2000-11-22
ID28232A (id)	2001-05-10
PT1123088E (pt)	2007-01-31
JP2002528408A (ja)	2002-09-03
ES2272082T3 (es)	2007-04-16
AP2001002125A0 (en)	2001-04-04
EA004068B1 (ru)	2003-12-25
KR20010075659A (ko)	2001-08-09
NZ510275A (en)	2003-07-25
BR9914718A (pt)	2001-07-10
AU5878799A (en)	2000-05-15
PL195789B1 (pl)	2007-10-31
CZ20011427A3 (cs)	2001-10-17
MA26700A1 (fr)	2004-12-20
OA11664A (en)	2005-01-07
BG65323B1 (bg)	2008-02-29

Publication	Publication Date	Title
ATE340562T1 (de)	2006-10-15	Cgmp pde-5 inhibitor enthaltende pharmazeutische formulierungen mit verzögerter freisetzung
DE69924999D1 (de)	2005-06-02	Lipasehemmer enthaltende pharmazeutische zusammensetzungen
ATE320244T1 (de)	2006-04-15	Pharmazeutische zusammensetzungen mit amlodipinmaleat
AU9208601A (en)	2002-04-22	Delayed release pharmaceutical formulations
DK1600154T3 (da)	2011-02-21	Osmotisk doseringsform med forlænget frigivelse
ATE222751T1 (de)	2002-09-15	Pharmazeutische aerosolzusammensetzung
ATE228823T1 (de)	2002-12-15	Pharmazeutische aerosolformulierung
ATE306253T1 (de)	2005-10-15	Orale bioadhäsive tablette mit verlängerter wirkstoffabgabe
ATE201986T1 (de)	2001-06-15	Kaffein-formulierung mit verzögerter freisetzung
EP1411904A4 (de)	2006-06-07	Pharmazeutische zusammensetzung mit verzögerter freisetzung
DE69721559D1 (de)	2003-06-05	Geschmacksmaskierte pharmazeutische dosisform mit schneller freisetzung
ATE254907T1 (de)	2003-12-15	Natriumhydrogendivalproat-formulierungen mit gesteuerter freigabe
DE60210139D1 (de)	2006-05-11	Pharmazeutische zusammensetzungen enthaltend tegaserod
NO20002126L (no)	2000-05-04	Formulering med forlenget frigjøring
HUP0301177A3 (en)	2006-07-28	Ion-strength independent sustained release pharmaceutical formulation
DE59910298D1 (de)	2004-09-23	Pharmazeutische levothyroxinzubereitung
ATE350016T1 (de)	2007-01-15	Bicalutamid enthaltende pharmazeutische zusammensetzung
DE19983627T1 (de)	2001-10-18	Knoblauch-Formulierungen mit kontrollierter Freisetzung
ATE295150T1 (de)	2005-05-15	Pharmazeutische zusammensetzungen
NO984035L (no)	1998-10-22	Farmas°ytiske formuleringer med forlenget frigivelse inneholdende mizolastin
ATE412405T1 (de)	2008-11-15	Pharmazeutische zusammensetzung mit modifiziertem träger
DE69816124D1 (de)	2003-08-07	Pharmazeutische zusammensetzungen enthaltend zafirlukast
EP1124557A4 (de)	2002-08-07	Pharmazeutische zusammensetzung
DE10291905D2 (de)	2004-05-27	Pharmazeutische Zusammensetzung
ATE350029T1 (de)	2007-01-15	Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain

Legal Events

Date	Code	Title	Description
2007-01-15	UEP	Publication of translation of european patent specification	Ref document number: 1123088 Country of ref document: EP
2010-07-15	REN	Ceased due to non-payment of the annual fee

Date

Code

Title

Description

2007-01-15

UEP

Publication of translation of european patent specification

Ref document number: 1123088

Country of ref document: EP

2010-07-15

REN

Ceased due to non-payment of the annual fee